Researchers at Boston University have developed a multi-ancestry polygenic risk score for Alzheimer's disease that significantly improves risk prediction across diverse racial and ethnic populations.
The genomic tools used to forecast Alzheimer’s disease were overwhelmingly built on data from people of European descent. That left millions of African American, Hispanic, and East Asian patients with risk scores that simply did not work. A multi-ancestry polygenic risk score developed by Boston University researchers changes this paradigm. It offers a vastly more reliable way to estimate genetic susceptibility across diverse populations.
Understanding the Multi-Ancestry Breakthrough
Led by Dr. Lindsay A. Farrer and Dr. Xiaoling Zhang at the Boston University Chobanian & Avedisian School of Medicine, researchers set out to correct a massive demographic imbalance in genome-wide association studies (GWAS). Earlier models relied heavily on white European cohorts. When applied elsewhere, their predictive accuracy plummeted. The team utilized summarized genetic marker data from more than 63,000 Alzheimer’s cases and 484,000 age-matched controls representing multiple ancestral groups.
The resulting polygenic risk score (PRS)—a numerical estimate of an individual’s inherited susceptibility to a specific condition—was tested in an independent sample of 10,612 Alzheimer’s cases and 16,625 elderly controls. It was later validated in a mixed group of 1,500 cases and 75,500 elderly controls. Compared to legacy tools, this new metric proved far more accurate in forecasting a clinical diagnosis of Alzheimer’s disease among African American, Caribbean and continental Hispanic, and East Asian populations.
In Plain English: The Clinical Takeaway
- Beyond Simple Diagnosis: The score correlates directly with real biological changes, including memory decline, hippocampal shrinkage, and abnormal brain proteins.
- Clinical Trial Matching: By identifying high-risk individuals earlier, doctors can better match diverse patients to appropriate preventative trials and monitoring protocols.
Biological Correlates and Clinical Validation
The utility of this new score extends well beyond slapping a label of high or low risk on a patient. Investigators evaluated the PRS against a battery of clinical, neuroimaging, and biomarker traits drawn from major initiatives like the Alzheimer’s Disease Sequencing Project, the Framingham Heart Study, the Alzheimer’s Disease Neuroimaging Initiative, and the Korean Brain Aging Study for the Early Diagnosis and Prediction of AD. The findings confirm that high PRS values track closely with physical deterioration in the brain.
Specifically, researchers tied high scores to poorer performance in memory, executive function, and language. Brain magnetic resonance imaging (MRI) scans revealed a reduced volume in the hippocampus, the vital anatomical structure most vulnerable during the early stages of the disease. Furthermore, cerebrospinal fluid analyses showed abnormal concentrations of hallmark pathological proteins, including amyloid-beta and phosphorylated tau (pTau), with women exhibiting an even greater deviation in pTau levels.
| Study Cohort / Phase | Sample Size (Cases / Controls) | Primary Populations Evaluated |
|---|---|---|
| GWAS Training Set | 63,000+ Cases / 484,000+ Controls | Multi-ancestry (European, African American, Hispanic, East Asian) |
| Independent Testing Sample | 10,612 Cases / 16,625 Controls | Diverse ancestral groups |
| Validation Group | 1,500 Cases / 75,500 Controls | Mixed ancestry |
Funding Transparency and Regulatory Implications
By proving that multi-ancestry cohorts yield clinically superior predictive models, this research provides a vital framework for regulatory bodies such as the U.S. Food and Drug Administration (FDA) and international agencies evaluating genetic diagnostics.
Contraindications & When to Consult a Doctor
Looking Ahead
Longitudinal analyses revealed that individuals possessing a very high polygenic risk score experienced a steeper trajectory of cognitive decline over time. By bridging the genetic equity gap, this research opens the door for earlier clinical intervention, targeted lifestyle counseling, and more inclusive recruitment for upcoming therapeutic trials.
